Skip to main content

Marina Publishes Animal Data on Liposomal Delivery System

Premium

Marina Biotech this week announced that it has published preclinical data showing the use of its DiLA2 liposomal delivery technology for systemic administration of siRNAs against a number of liver targets.

According to the paper, which appeared in Molecular Therapy, one formulation resulted in greater than 80 percent knockdown of apolipoprotein B, transthyretin, factor VII, and proprotein convertase subtilisin/kexin type 9 mRNA when administered systemically in a 2 mg/kg dose to animal models.

“The formulation was well tolerated with single- and multiple-dose regimens,” Marina said. “Additionally, when stored frozen, DiLA2-based formulations demonstrated physical and chemical stability for greater than one year.”

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.